Roche has decided to pay $190 million upfront for an unusual obesity mechanism after viewing preclinical data that “clearly suggests” the modality can reduce weight while preserving lean muscle, Fierce has learned.
Roche has decided to pay $190 million upfront for an unusual obesity mechanism after viewing preclinical data that “clearly suggests” the modality can reduce weight while preserving lean muscle, Fierce has learned.
